Market Overview

Aptose to Release Fourth Quarter and Year End December 31, 2019 Financial Results and Hold Conference Call on March 10, 2020


SAN DIEGO and TORONTO, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter and year ended December 31, 2019, on Tuesday, March 10, 2020 after the close of the market.

Conference Call & Webcast:

Date: Tuesday, March 10, 2020
Time: 5:00 PM Eastern Time
Dial In - Toll-Free: 1 844-882-7834
Dial In - International: 1 574-990-9707
Passcode: 1097606
Webcast: LINK

Replay available through March 17, 2020:

Dial In - Toll-Free: 1 855-859-2056
Dial In - International: 1 404-537-3406
Replay Passcode: 1097606

The live conference call can also be accessed through a link on the Investor Relations section of Aptose's website at An archived version of the webcast along with a transcript will be available on the company's website for 30 days.

The press release, the financial statements and the management's discussion and analysis for the quarter ended and year ended December 31, 2019 will be available on SEDAR at and EDGAR at

About Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies; APTO-253, the only clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS). For further information, please visit

For further information, please contact:

Aptose Biosciences Inc. LifeSci Advisors, LLC
Greg Chow Dan Ferry, Managing Director
Senior Vice President, CFO 617-535-7746
SMP Communications  
Susan Pietropaolo  

Primary Logo

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at